Go to
JCI Insight
About
Editors
Consulting Editors
For authors
Publication ethics
Publication alerts by email
Advertising
Job board
Contact
100th anniversary
Current issue
Past issues
By specialty
COVID-19
Cardiology
Gastroenterology
Immunology
Metabolism
Nephrology
Neuroscience
Oncology
Pulmonology
Vascular biology
All ...
Videos
Conversations with Giants in Medicine
Video Abstracts
Reviews
Reviews
View all reviews ...
Review Series
Substance Use Disorders (Oct 2024)
Clonal Hematopoiesis (Oct 2024)
Sex Differences in Medicine (Sep 2024)
Vascular Malformations (Apr 2024)
Lung inflammatory injury and tissue repair (Jul 2023)
Immune Environment in Glioblastoma (Feb 2023)
Korsmeyer Award 25th Anniversary Collection (Jan 2023)
View all review series ...
Viewpoint
Collections
In-Press Preview
Clinical Medicine
Research Letters
Letters to the Editor
Editorials
Commentaries
Reviews
Viewpoints
Top read articles
Clinical Medicine
Citations to this article
Concerns about the inverse relationship between baseline HBV DNA and on-treatment hepatocellular carcinoma risk
Shi Liu, … , Yongyin Li, Jian Sun
Shi Liu, … , Yongyin Li, Jian Sun
Published August 1, 2022
Citation Information:
J Clin Invest.
2022;
132(15)
:e161134.
https://doi.org/10.1172/JCI161134
.
View:
Text
|
PDF
Letter to the Editor
Hepatology
Concerns about the inverse relationship between baseline HBV DNA and on-treatment hepatocellular carcinoma risk
Text
PDF
Abstract
Authors
Shi Liu, Yongyin Li, Jian Sun
×
Loading citation information...
Advertisement
